Tutorials

Vedanta Ltd witnessed a sharp decline in its share price, falling as much as 8% intraday after U.S.-based short-seller Viceroy Research revealed a short position against its parent company, Vedanta Resources. This move has reignited concerns around corporate governance, debt sustainability, and financial transparency within the Vedanta Group structure. Background: Why Did the Stock Fall? Viceroy Research published a detailed report accusing Vedanta Resources of using its Indian-listed subsidiary, Vedanta Ltd, to service its debt Read More

Indian equity markets extended their upward momentum today, fueled by optimism surrounding an impending global trade deal. The benchmark Nifty 50 surged past the 25,500 mark, while the Sensex climbed over 300 points, signaling strong investor confidence and positive macroeconomic sentiment. Volatility also eased notably, with the India VIX cooling down by 3%, indicating reduced fear in the markets. Let’s break down the factors driving today’s rally and what it means for the market going Read More

The Bombay Stock Exchange (BSE) has witnessed a sharp correction in its stock price over the past few sessions, triggered by regulatory actions and broader market caution. After peaking at record highs earlier this month, the stock has declined nearly 21% from its all-time high and has tanked 15% in just three trading sessions following the SEBI action against U.S.-based trading firm Jane Street. This sudden and steep decline has raised questions in the investor Read More

Indian pharmaceutical stocks witnessed a significant drop of up to 3% on July 8, 2025, driven by renewed concerns over potential U.S. import tariffs on generic drugs and pharmaceuticals. Leading the fall were shares of key drug manufacturers such as Aurobindo Pharma, Lupin, and Dr. Reddy’s Laboratories, all of which have substantial exposure to the U.S. market. Key Stock Movements Aurobindo Pharma fell approximately 3%, trading near ₹1,147 Lupin saw a similar 3% decline, down Read More

Adani Enterprises Limited (AEL) has announced the launch of its second public issue of secured, rated, listed non-convertible debentures (NCDs), aiming to raise up to ₹1,000 crore. This issue comes after the success of the company’s maiden NCD issue last year, which was fully subscribed on the first day. Details of the NCD Issue Issue Size: Base issue size of ₹500 crore Green-shoe option of ₹500 crore Total size up to ₹1,000 crore Opening and Read More